AI assistant
Evotec SE — Regulatory Filings 2015
Mar 13, 2015
151_rns_2015-03-13_6903e601-1e0b-48bc-a7d1-e30ac15c79a2.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 13 March 2015 07:31
Second Genome and Evotec to collaborate in microbiome discovery and development
DGAP-News: Evotec AG / Key word(s): Miscellaneous
2015-03-13 / 07:31
Hamburg, Germany - 13 March 2015: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) and Second Genome, Inc. today announced a
collaboration in small molecule-based discovery and development activities
for the treatment of microbiome-mediated diseases. The collaboration
comprises the identification and optimisation of novel compounds as well as
licence agreements for already existing assets developed by Evotec. Second
Genome's unique approach to identify and modulate microbiome-mediated
pathways will be further enhanced by the use and the results of Evotec's
integrated drug discovery platform.
As part of the collaboration, Second Genome and Evotec will work together
to screen microbiome-mediated targets of interest identified by the Second
Genome microbiome discovery platform with Evotec's technology platform,
chemical libraries and other pre-clinical capabilities. The agreement
between Evotec and Second Genome triggers an undisclosed upfront payment.
Evotec is also eligible for pre-clinical, clinical and regulatory
milestones as well as royalty payments related to commercialisation.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are
pleased to contribute to Second Genome's unique approach to treat
microbiome-mediated diseases in the body with a particular emphasis on the
gut. The enrichment and maturation of Second Genome's project portfolio
through our contributions will enhance the Company's clinical pipeline in
the near future."
Mohan Iyer, Chief Business Officer of Second Genome, added: "The
partnership with Evotec allows us efficiently to translate our unique
microbiome discovery platform efficiently into tangible drug molecules for
clinical development. Our enriched pipeline offers new treatment approaches
for patients across a wide range of diseases with an initial focus on
inflammatory conditions. We look forward to a sustained partnership with
Evotec."
Further financial terms were not disclosed.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
ABOUT SECOND GENOME
Second Genome's mission is to transform lives with medicines developed
through innovative microbiome science. Second Genome has built a novel
platform for microbiome drug discovery and is engaged in active programmes
in multiple areas of significant unmet medical need Please visit
www.secondgenome.com for more information.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
2015-03-13 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart
End of News DGAP News-Service
332887 2015-03-13